Kobayashi Pharmaceutical Co., Ltd. Stock OTC Markets

Equities

KBYPF

JP3301100008

Personal Products

Market Closed - OTC Markets 03:32:07 2024-03-27 pm EDT 5-day change 1st Jan Change
32.48 USD -16.56% Intraday chart for Kobayashi Pharmaceutical Co., Ltd. -.--% -26.22%
Days
Hours
Minutes
Seconds
-40%
on all our subscriptions*
Last Hours!
Take advantage of the offer
* See conditions on site
Sales 2024 * 178B 1.14B Sales 2025 * 188B 1.21B Capitalization 414B 2.66B
Net income 2024 * 17.68B 114M Net income 2025 * 20.65B 133M EV / Sales 2024 * 1.92 x
Net cash position 2024 * 72.61B 466M Net cash position 2025 * 79.28B 509M EV / Sales 2025 * 1.77 x
P/E ratio 2024 *
22.8 x
P/E ratio 2025 *
20.1 x
Employees 3,534
Yield 2024 *
1.85%
Yield 2025 *
1.88%
Free-Float 59.84%
More Fundamentals * Assessed data
Dynamic Chart
A second Kobayashi Pharma Japan factory inspected over deaths RE
Kobayashi factory searched over deaths possibly linked to supplements RE
Kobayashi Pharmaceutical Recalls 'Beni-Koji' Supplement Following Report of Death, Kidney Damage MT
Tranche Update on Kobayashi Pharmaceutical Co., Ltd.'s Equity Buyback Plan announced on November 7, 2023. CI
Kobayashi Pharmaceutical Co., Ltd's Equity Buyback announced on November 7, 2023, has closed with 1,924,600 shares, for ¥11,999.88 million. CI
Kobayashi Pharmaceutical Co., Ltd. acquired Focus Consumer Healthcare, LLC. CI
Kobayashi Pharmaceutical Co., Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2023 CI
Organ Technologies Inc announced that it has received funding from Kobayashi Pharmaceutical Co., Ltd. CI
Tranche Update on Kobayashi Pharmaceutical Co., Ltd.'s Equity Buyback Plan announced on November 1, 2022. CI
Kobayashi Pharmaceutical Co., Ltd.'s Equity Buyback announced on November 1, 2022, has closed with 1,150,602 shares, representing 1.49% for ¥9,991.92 million. CI
Kobayashi Pharmaceutical Co., Ltd. announces an Equity Buyback for 1,265,800 shares, representing 1.64% for ¥9,999.82 million. CI
Kobayashi Pharmaceutical Co., Ltd. authorizes a Buyback Plan. CI
Kobayashi Pharmaceutical Co., Ltd. Provides Earnings Guidance for the Full Year 2022 CI
UBS Adjusts Kobayashi Pharmaceutical's Price Target to 12,600 Yen From 13,100 Yen, Keeps at Buy MT
Tranche Update on Kobayashi Pharmaceutical Co., Ltd.'s Equity Buyback Plan announced on October 28, 2021. CI
More news
1 day-16.56%
3 months-26.22%
6 months-26.22%
Current year-26.22%
More quotes
Current year
32.49
Extreme 32.485
38.93
1 year
32.49
Extreme 32.485
44.03
3 years
32.49
Extreme 32.485
85.30
5 years
32.49
Extreme 32.485
85.30
10 years
32.49
Extreme 32.485
85.30
More quotes
Managers TitleAgeSince
Chairman 84 62-02-28
Director of Finance/CFO - -
President 53 98-02-28
Members of the board TitleAgeSince
Director/Board Member 91 08-05-31
President 53 98-02-28
Chairman 84 62-02-28
More insiders
KOBAYASHI PHARMACEUTICAL CO., LTD. a drug manufacturer. The Company operates in three segments. The Domestic Household Products Manufacturing and Sales segment and Overseas Household Products Manufacturing and Sales segment offer health care, daily necessities, skin care and other products. The Mail Order segment involves in the mail order of dietary supplements, skin care products and others.
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
More Ratings
Sell
Consensus
Buy
Mean consensus
HOLD
Number of Analysts
6
Last Close Price
5,564 JPY
Average target price
6,565 JPY
Spread / Average Target
+17.99%
Consensus
-40% Limited Time Offer: Our subscriptions help you unlock hidden opportunities.
BENEFIT NOW